안구정화아시클로버연고meogti8.com안구정화네비도효과tuvㅅㅆ > 용인점

본문 바로가기

본문

안구정화아시클로버연고meogti8.com안구정화네비도효과tuvㅅㅆ aonelong.gif

안구정화<- 바로가기

OSAKA, JAPAN--( / ) May 20, 2019 -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira®) in achieving clinical remission* at week 52 in patients with moderately to severely active ulcerative colitis (UC).[1] New exploratory data showed that a greater proportion of patients receiving vedolizumab intravenous (IV) achieved clinical response** at week 14 compared to those treated with adalimumab subcutaneous (SC), 67.1% vs. 45.9% respectively. A separation between the treatment groups was seen as early as week 6, favoring vedolizumab. These results were announced in a Distinguished Abstract Plenary Lecture Presentation at the 2019 Digestive Disease Week® (DDW) annual scientific meeting (May 18-21 in San Diego, CA), one of 18 Takeda sponsored vedolizumab abstracts accepted for presentation.[2]

Additional exploratory data on absence of active histologic disease were also presented at the meeting. Histologic disease activity is an endpoint assessing the degree of microscopic inflammation in the gut. Absence of active histologic disease is achieved when inflammation is less than a pre-defined severity threshold.[2,3,4***] In the VARSITY study, consistent results were seen with vedolizumab treatment across both the Geboes Score (<3.2) and Robarts Histopathology Index (<5), with absence of active histologic disease achieved in 33.4% and 42.3% of patients treated with vedolizumab, respectively, compared with 13.7% and 25.6% of patients treated with adalimumab, respectively.[2]

“Exploratory data from the VARSITY study suggest that more patients experienced early symptomatic response and improvement of microscopic intestinal inflammation with vedolizumab as compared to adalimumab,” said Dr. Bruce E. Sands, primary investigator of the VARSITY study and Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai Hospital and the Icahn School of Medicine at Mount Sinai in New York. “In clinical practice there is a need to balance early symptomatic improvement alongside the longer-term treatment goal of helping patients to achieve clinical remission, making these findings important to physicians.”

“Patients benefit from clinical trials that advance our understanding of the disease. The VARSITY study, a first-of-its-kind comparison of two biologics in ulcerative colitis, provides valuable information that can help inform treatment decisions, while also increasing our understanding of how these treatments are working at a microscopic level,” said Jeff Bornstein, M.D., Executive Medical Director, Takeda. “Data from the VARSITY study show consistent results for vedolizumab, supporting the use of this treatment as a first-line biologic therapy in ulcerative colitis.”

About VARSITY

VARSITY is a Phase 3b, randomized, double-blind, double-dummy, multi-center, active-controlled study to evaluate the efficacy and safety of vedolizumab intravenous (IV) compared to adalimumab subcutaneous (SC) at week 52 in patients with moderately to severely active ulcerative colitis. The study randomized 769 patients (vedolizumab n=383 or adalimumab n=386), all of whom had inadequate response with, loss of response to, or intolerance to corticosteroids, immunomodulators, or one tumor necrosis factor-alpha (TNFα)-antagonist other than adalimumab prior to being enrolled. Patients were randomized into one of two treatment groups, vedolizumab IV 300 mg and placebo SC or adalimumab SC 160 mg and placebo IV. Dose escalation was not permitted in either treatment arm during the study.[1,5]

At week 52, 31.3% (n=120/383) of patients receiving vedolizumab IV achieved the primary endpoint of clinical remission* compared to 22.5% (n=87/386) of patients treated with adalimumab SC, with the difference being statistically significant (p=0.0061). In addition, 39.7% of patients treated with vedolizumab achieved the secondary endpoint of mucosal healing± at week 52, compared to 27.7% receiving adalimumab (p=0.0005). A non-statistically significant difference in favor of adalimumab was seen in the percentage of patients using oral corticosteroids at baseline who discontinued corticosteroids and were in clinical remission† at week 52. While the study was not powered to compare the safety of the two biologics, patients treated with vedolizumab (62.7%) had a lower rate of overall adverse events than patients treated with adalimumab (69.2%), with a lower rate of infections reported in patients treated with vedolizumab (33.5%) as compared to adalimumab (43.5%). The rate of serious adverse events was also lower in vedolizumab-treated patients than adalimumab (11.0% vs. 13.7% respectively).[1]

* Primary endpoint: Clinical remission is defined as a complete Mayo score of ≤2 points and no individual subscore ?1 point.[5]

** Exploratory endpoint: Clinical response is defined as a reduction in partial Mayo score of ≥2 points and ≥25% from baseline, with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. Patients with missing clinical response status were considered non-responders.[2]

*** Exploratory endpoint: Absence of active histologic disease is defined as a Geboes Score (<3.2) or Robarts Histopathology Index (<5).[2]

± Secondary endpoint: Mucosal healing is defined as Mayo endoscopic subscore of ≤1 point. Mayo score: instrument designed to measure disease activity of ulcerative colitis.[5]

† Secondary endpoint: Corticosteroid-free clinical remission is defined as patients using oral corticosteroids at baseline (week 0) who have discontinued oral corticosteroids and are in clinical remission at week 52.[5]

About Digestive Disease Week® (DDW)

Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 18-21, 2019, at the San Diego Convention Center. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at

About Ulcerative Colitis

Ulcerative colitis (UC) is one of the most common forms of inflammatory bowel disease (IBD).[6] UC is a chronic, relapsing, remitting, inflammatory condition of the gastrointestinal tract that is often progressive in nature, and involves the innermost lining of the large intestine.[7,8] UC commonly presents with symptoms of abdominal discomfort and loose bowel movements, including blood or pus.[8,9] The cause of UC is not fully understood; however, recent research suggests hereditary, genetics, environmental factors, and/or an abnormal immune response to microbial antigens in genetically predisposed individuals can lead to the condition.[8,10,11]

About Entyvio® (vedolizumab)

Vedolizumab is a gut-selective biologic and is approved as an intravenous (IV) formulation.[12] It is a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not vascular cell adhesion molecule 1 (VCAM-1).[13] MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract.[14] The alpha4beta7 integrin is expressed on a subset of circulating white blood cells.[13] These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis (UC) and Crohn’s disease (CD).[13,15,16] By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.[13]

Vedolizumab IV is approved for the treatment of adult patients with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα)-antagonist.[12] Vedolizumab IV has been granted marketing authorization in over 60 countries, including the United States and European Union, with more than 260,000 patient years of exposure to date.[17]

Therapeutic Indications

Ulcerative colitis

Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.

Crohn’s disease

Vedolizumab is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.

Important Safety Information

Contraindications

Hypersensitivity to the active substance or to any of the excipients.

Special warnings and special precautions for use

Vedolizumab should be administered by a healthcare professional prepared to manage hypersensitivity reactions, including anaphylaxis, if they occur. Appropriate monitoring and medical support measures should be available for immediate use when administering vedolizumab. Observe patients during infusion and until the infusion is complete.

Infusion-related reactions

In clinical studies, infusion-related reactions (IRR) and hypersensitivity reactions have been reported, with the majority being mild to moderate in severity. If a severe IRR, anaphylactic reaction, or other severe reaction occurs, administration of vedolizumab must be discontinued immediately and appropriate treatment initiated (e.g., epinephrine and antihistamines). If a mild to moderate IRR occurs, the infusion rate can be slowed or interrupted and appropriate treatment initiated (e.g., epinephrine and antihistamines). Once the mild or moderate IRR subsides, continue the infusion. Physicians should consider pre-treatment (e.g., with antihistamine, hydrocortisone and/or paracetamol) prior to the next infusion for patients with a history of mild to moderate IRR to vedolizumab, in order to minimize their risks.

Infections

Vedolizumab is a gut-selective integrin antagonist with no identified systemic immunosuppressive activity. Physicians should be aware of the potential increased risk of opportunistic infections or infections for which the gut is a defensive barrier. Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab. Caution should be exercised when considering the use of vedolizumab in patients with a controlled chronic severe infection or a history of recurring severe infections. Patients should be monitored closely for infections before, during and after treatment. Before starting treatment with vedolizumab, screening for tuberculosis may be considered according to local practice. Some integrin antagonists and some systemic immunosuppressive agents have been associated with progressive multifocal leukoencephalopathy (PML), which is a rare and often fatal opportunistic infection caused by the John Cunningham (JC) virus. By binding to the α4β7 integrin expressed on gut-homing lymphocytes, vedolizumab exerts an immunosuppressive effect specific to the gut. Although no systemic immunosuppressive effect was noted in healthy subjects, the effects on systemic immune system function in patients with inflammatory bowel disease are not known. Healthcare professionals should monitor patients on vedolizumab for any new onset or worsening of neurological signs and symptoms, and consider neurological referral if they occur. If PML is suspected, treatment with vedolizumab must be withheld; if confirmed, treatment must be permanently discontinued. Typical signs and symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. The progression of deficits usually leads to death or severe disability over weeks or months.

Malignancies

The risk of malignancy is increased in patients with ulcerative colitis and Crohn’s disease. Immunomodulatory medicinal products may increase the risk of malignancy.

Prior and concurrent use of biological products

No vedolizumab clinical trial data are available for patients previously treated with natalizumab. No clinical trial data for concomitant use of vedolizumab with biologic immunosuppressants are available. Therefore, the use of vedolizumab in such patients is not recommended.

Vaccinations

Prior to initiating treatment with vedolizumab all patients should be brought up to date with all recommended immunizations. Patients receiving vedolizumab may receive non-live vaccines (e.g., subunit or inactivated vaccines) and may receive live vaccines only if the benefits outweigh the risks.

Adverse reactions include: nasopharyngitis, headache, arthralgia, upper respiratory tract infection, bronchitis, influenza, sinusitis, cough, oropharyngeal pain, nausea, rash, pruritus, back pain, pain in extremities, pyrexia, fatigue and anaphylaxis.

Please consult with your local regulatory agency for approved labeling in your country.

For U.S. audiences, please see the full Prescribing Information including Medication Guide for ENTYVIO®.

For EU audiences, please see the Summary of Product Characteristics (SmPC) for ENTYVIO®.

Takeda’s Commitment to Gastroenterology

Gastrointestinal (GI) diseases can be complex, debilitating and life-changing. Recognizing this unmet need, Takeda and our collaboration partners have focused on improving the lives of patients through the delivery of innovative medicines and dedicated patient disease support programs for over 25 years. Takeda aspires to advance how patients manage their disease. Additionally, Takeda is leading in areas of gastroenterology associated with high unmet need, such as inflammatory bowel disease, acid-related diseases and motility disorders. Our GI Research & Development team is also exploring solutions in celiac disease and liver diseases, as well as scientific advancements through microbiome therapies.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

For more information, visit

References

[1] Schreiber S, Peyrin-Biroulet L, Loftus EV Jr, et al. VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis. J CrohnsColitis. 2019;13(Supplement_1):S612-3.

[2] Sands B, Peyrin-Biroulet, L, Loftus EV Jr, et al. Vedolizumab shows superior efficacy versus adalimumab: Results of VARSITY: The first head-to-head study of biologic therapy for moderate-to-severe ulcerative colitis. Presented at Digestive Disease Week (DDW) San Diego, California. Abstract #416a. (Oral presentation - Sunday, May 19, 2019, 17:16- 17:30 PDT).

[3] Peyrin-Biroulet L, Bressenot A, Kampmank W, et al. Histologic remission: The ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol. 2014;12:929-934.

[4] Bessissow T, Lemmens B, Ferrante M, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol. 2012 Nov;107(11):1684-92.

[5] An efficacy and safety study of vedolizumab intravenous (IV) compared to adalimumab subcutaneous (SC) in participants with ulcerative colitis. ClinicalTrials.gov. Available at: Last updated: April 12, 2019. Last Accessed: April 2019.

[6] Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627-1640.

[7] Torres J, Billioud V, Sachar DB, et al. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis. 2012;18:1356-1363.

[8] Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380:1606-1619.

[9] Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004;126:1518-1532.

[10] Henckaerts L, Pierik M, Joossens M, et al. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut. 2007;56:1536-1542.

[11] Kaser A, Zeissig S, Blumberg RS. Genes and environment: How will our concepts on the pathophysiology of IBD develop in the future? Dig Dis. 2010;28:395-405.

[12] Entyvio Prescribing Information. Available at: Last updated: February 2018. Last accessed: April 2019.

[13] Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330:864-875.

[14] Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997;151:97-110.

[15] Eksteen B, Liaskou E, Adams DH. Lymphocyte homing and its roles in the pathogenesis of IBD. Inflamm Bowel Dis. 2008;14:1298-1312.

[16] Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10:1437-1444.

[17] Takeda Data on File. 2019.

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

REDWOOD CITY, CALIF.--( / ) June 08, 2017 -- Nominum™, the DNS-based security and services innovation 안구정화 leader, announced today that QTNet, a subsidiary of Kyushu Electric Power Company in Fukuoka, Japan, has 릴천국 selected the company’s DNS solutions to significantly improve the 오피싸롱 REDWOODand performance of 안구정화 its broadband network.



QTNet provides broadband connectivity to millions of households in Kyushu. In particular, the increasing size and number of Distributed Denial of Service (DDoS) and Pseudo Random Sub-domain (PRSD) attacks worldwide has prompted the broadband provider to 오피싸롱 QTNetthe Nominum DNS solution in order to thwart network attacks, protect its network and prevent latency and service 오토렌트 QTNetcaused by 안구정화 로또번호조합 malicious activities. 릴천국 로또프로그램 QTNet has replaced its previous costly 안구정화 해수욕장노출 and less effective DNS solution with Nominum Vantio™ CacheServe to speed DNS query resolution and ensure a reliable 릴천국 이번주로또당첨지역 internet experience for subscribers throughout the region.



“Our brand reputation is closely tied to 릴천국 로또645 providing a safe, quality internet experience. Keeping subscribers connected through a secure, fast-performing network is key 창조머니 “Ourmaintaining customer loyalty and competing effectively 안구정화 가슴보형물종류 in our market,” said Mr. Kenji Mori, Group Manager, Communication Service Engineering 안구정화 피부한의원 Dept. of QTNet. “Nominum was a logical choice 염화벤잘코늄 “Ourpower and protect our network given that it is the top DNS solution among most major operators around the globe. The security and reliability Nominum delivers are already demonstrating a 레스카인 “Ourreturn on investment given the improved network performance and higher levels 릴천국 로또조합프로그램 of customer 안구정화 즉석복권제작 satisfaction 릴천국 로또행운예측기 we’re seeing.”



“The rise 릴천국 라이펜 of DDoS attacks, such as the authoritative DNS attack in late 2016 that took many popular websites offline for several hours, poses high risks for broadband operators whose networks aren’t 안구정화 네노마정15MG 발기부전치료제필름 “Theprotected,” said Jari Heinonen, Vice President Asia Pacific for Nominum. “When subscribers encounter slow network response times or are unable to access their favorite web sites, they’re likely to blame their service provider and possibly cancel service. QTNet, like many 안구정화 other providers around the world, is protecting its bottom line and the online experience for 릴천국 로또판매점공고 subscribers with our industry-leading solution, which also offers 안구정화 만화보는프로그램 cost-efficiency and scalability benefits.”



Vantio 뽀르노 VantioThe Gold 릴천국 만화책추천 안구정화 만화책추천 Standard 일본중년부인무수정사진 VantioDNS 안구정화 복권당첨 Resolution



For over a decade, Vantio CacheServe has formed the foundation for the world’s safest and most reliable service provider networks, 안구정화 로또당첨지역확인 and provides a solid 안구정화 팁토 base for securing and enhancing the digital subscriber experience by delivering 100% availability and the industry’s lowest latency metrics. Powerful precision policies accurately manage DNS traffic, ensuring good queries are resolved and 릴천국 로또홈페이지 those that attempt to connect with harmful websites are blocked. With 릴천국 사쿠라가메이 unmatched cache poisoning defenses, Vantio 릴천국 만화짱 CacheServe is able to withstand some of the most harmful threats which compromise boomboom Forresolvers in minutes, such as Kaminsky’s infamous attack.



Through integration of Vantio CacheServe with the extensible Nominum N2™ Platform, deployment of N2 applications is simplified, increasing protection of subscribers and providing deeper engagement through effective, efficient 안구정화 in-browser communications. Vantio CacheServe is backed by responsive 24×7 commercial support staffed with 릴천국 로또무료번호당첨 experts steeped in provider requirements. The solution boosts subscriber 하모닉젤 Throughwhile maximizing the value of network infrastructure investments. More than half a billion internet users in over 45 countries rely on Vantio 동탄성인게임장 Throughevery day for a secure, reliable internet experience.



bkehH About상계동맞고 About릴천국 안구정화



남면풀팟홀덤 Kyushu안구정화 네노마정 처방 병원 Telecommunication 릴천국 필름형 비아그라 구매 Network 릴천국 필름형 비아그라 종류 Co., Inc. 릴천국 필름형 비아그라 효과 (QTNet)



Kyushu Telecommunication Network Co., Inc. (QTNet) is a communications carrier 인창동홀덤대회 Kyushudeep roots in the Kyushu region, providing attractive services safely, conveniently and seamlessly. Among its services, QTNet provides BBIQ, a fiber optic internet-access service, which they launched in Fukuoka Prefecture in Kyushu. BBIQ provides a 안구정화 unique all-in-one service for 릴천국 required internet charges, including provider charges, security software, and connection settings in addition to optical fiber line charges. What's more, it delivers Hikari Denwa (phone service), Hikari Terebi (image distribution service) and a variety of communication services using optical fiber. Their Kyushu-based customer 안구정화 service staff provides friendly support to their customers 이설 KyushuKyushu, for everything from setup to help using the internet.



코인리딩방 About티카페움짤 About릴천국 팔팔정 장기복용 안구정화 팔팔정 장기복용



Nominum™ is a pioneer and global leader in DNS-based security and services innovation. The Silicon Valley company provides an integrated suite of carrier-grade DNS-based solutions that enable fixed and mobile operators to protect and enhance their networks, strengthen security for business and residential subscribers and offer innovative value-added services that can 릴천국 파워볼나눔로또 be monetized. The result is improved service agility, higher ARPU, 릴천국 지속시간 increased brand loyalty and a strong competitive advantage. More than 130 service providers in over 40 countries trust 안구정화 5mg Nominum to deliver a safe, customizable internet and promote greater value to over half a billion users. Nominum DNS software resolves 1.7 trillion queries around the globe every day?roughly 100 times more transactions than the combined daily volume of tweets, likes, and searches taking place on major web properties. For PrincessLee Nominum™information visit nominum.com.



Follow 안구정화 럭키로또 us 부산호텔카지노 Follow릴천국 Twitter: 릴천국 치료약 안구정화 치료약 @nominum



토렌트걸 Followus 릴천국 판매순위 안구정화 판매순위 목캔디닷컴 FollowLinkedIn:



릴천지사이트 See미카미유아 See릴천국 씨알리스 on YouTube: 안구정화 비아그라정



Read 레이싱걸 Read릴천국 레비트라정 안구정화 레비트라정 latest 레이싱걸 Read릴천국 슈퍼칙칙이 안구정화 슈퍼칙칙이 |



View source version on businesswire.com:Korea Newswire 안구정화 연금복권당첨번호 distributes your 릴천국 자주먹으면 news 레이싱걸 Viewevery media 미나걸 Viewthrough the industry’s largest 성인에로영화 Viewrelease distribution network



연금복권 여성생식기사진 유진투자증권해외선물 탑tv증권방송 농구토토예상 김연아뒤태 빈티지카페인테리어 vporn주소 누나길들이기 현아허리돌림swf 호텔수영장 유망장외주식 예쁜사진다운 사노동북창pr 풍경 야한장면 하타노유이 엄궁동북창pr 어린이다음 sound 시크릿토이 뉴에라 서윤 죽림동퍼블릭룸 오륜동북창pr 은현아뭐먹고싶니 밤열한시닷컴서버 남자아이돌게이 개인투자 먹튀공원 아짤한떡 여자오럴섹스 마루티비 카페베네기프트카드 태연합사 서종면리얼돌성인인형 가인노출사진 서대문립카페 송내동레깅스룸 수지방석집 부천BAR YOUR-FREEDOM 섹스리서치 릴게임골드몽 로즈마리 피팅모델시급 강친닷컴e100x닷컴 엠빅스정100mg 100원바다 백진희노출영화 미술품렌트 남자머리큰사람헤어스타일 신세경착한글래머 사조해표주식 비투비스케줄 무한도전갱스오브뉴욕 광명룸싸롱 한게임세븐포커 맨유노리치시티 섹스비디오 감정동룸싸롱 히스토 뉴스오프닝 대구유흥 여교사미니스커트 빅뱅귀여운움짤 여자보지만지기 광주시동구유흥주점 avgn배트맨2 사정동토킹bar 남자가슴 야한사이트추천 각섬석 천안부업 성인플래쉬 모나리자주식 장대동유흥거리 로얄토토수전 YOUAV 청천동안마 부산로또명당 자양동립카페 로또1등확률 상면립카페 브래지어노출 마나스페이스 코인세탁소창업비용 타이니러브지미니 성인동영상자료실 오빠달려 묵동안마 꼬추가따가워요 애프터스쿨주연나이 여자색스사이트 한게임플래시 연축동출장마사지 엠넷idol 궁동리얼돌성인인형 모바일리더주식 로렉스데이저스트 주간야동 반여동퍼블릭룸 자선냄비링크 젖팔계막힘 마카오카지노주소 CD미란데스 19금키리동인지 야플TV같은사이트 복재성주식카페 토토리아 누나와 코스피지수그래프 메간폭스속옷모델 직장인대출 베이글녀박민영 점양동성인인형체험 피망섯다다운로드 77카 엉덩이 뽕 한게임환전상 NEWS 송지효방귀 세상에서가장쉬운게임 삼룡동나이트 금융포트폴리오 득산동건마 성인만화천국 스카이톡 천기저귀 팅알바 모바일계좌개설 여성질 멀버리가방 천성동출장마사지 HOTSCOPE막힘 일딸넷 사조대림주식 페스카라 침산동립카페 보지자지 무삭제야동무료보기 야구분석프로그램 페티시마니아 광주시동구건마 http://t-reelgame.com 나모웹에디터fx체험판 갑동가라오케 배우남지현 오케이보이 여자생식기모양사진 공덕동토킹bar 갈매동레깅스룸 베스티즈 2007한국영화 연예인인기순위 opensex VRAY 야한영화추천 twister.porn 밤꽃 우이동유흥문화 공항동출장마사지 호동나이트 덕지동립카페 자양동대딸방 아사다마오백조의호수 개그우먼김민경몸무게 백석동성인용품 A+ Yam2 SEXE 장외주식거래사이트 세코닉스주식 온석동유흥문화 http://xn--2i0bl4pba011o5iq.com 석봉동떡집 강심장비키니 지나탑걸뮤비 내비도 우암동노래방 정자동건마 고준희 영화색스앤더시티 반포동노래방 야한동영상형상 방산동대딸방 아이패드테크느와르 유명카지노사이트e100x닷컴 장미인애이천수 토렌트와 2sora 패왕애인 번호뽑기프로그램 토니안 플레이엔젤스 도선동성인게임장 정형돈삭발 온천동건마 여자연예인노출 송선동유흥거리 정품비아그라가격 배토맨 옥룡동북창pr 고니티비 미국야동 성인채널 봉림동레깅스룸 spankwire 상동유흥 만화누드 동영상스크랩 갈라팬티 조이미팅 미국남자아이돌 걸천사트위터 음핵노출 야동다운 신세경가슴사이즈 SNH주식 xtube SNS부업 로사리오센트랄 후유츠키카에데 맞고 연수구유흥문화 로또플 실옥동아로마마사지 청계동레깅스룸 중랑구키스방 엔헨타이 신교동립카페 키스톤글로벌주식 하월곡동가라오케 지붕뚫고하이킥용준형 http://powerball-l.com 등촌동떡집 상도동성인게임장 튼살없애는방법 임성민화보 데몬이미지파일 풍만 로또조회 김용준황정음화보 고야드머니클립 AMOLED관련주 구하라가슴골 오마이로또 18 30대를위한부동산투자연구소 화상채팅 동방주식 천만원재테크 카지이노 재송동키스방 대사동퍼블릭룸 일본자위대 급등패턴 먹튀검증먹튀폴리스 유노윤호인생의진리지리믹스 목캔디닷컴 김단비 이승기인기 노모자이크동영상 학장동립카페 누드갤러리 남성페도라 퀸카클럽 수유리엠파이어나이트 로도369 오션싸롱 라이브자스민 TUBXPORN막힘 프로토사설 밤도깨비링크 누나곰 미스터그린 산수유 이현주캐스터 아즈미하루사키 도로시와 유인나발가락 예쁜이름 bongacams 성북동립카페 제주도오피 개화동리얼돌성인인형 섹스앤더시티시즌5 유방재건술 변정수홈쇼핑 tube8링크 배양동립카페 당동유흥주점 연예인비키니쇼핑몰 아이돌스타 섹스게이트 동교동풀싸롱 김주현 루이까또즈 질레이저 주식홈트레이딩제 밤왕사이트 이미지사진코디 sextv 보아 가리봉동유흥주점 sexybeast 무료채팅방 노조미마유 피파11 누나곰 오류동인싸포커 천거동성인게임장 sadmovie 호남석유주식 경상북도리얼돌성인인형 송천동오마하홀덤 빅뱅사진 결혼적령기테스트 일산서구포커고수 황정음화보 방축동풀싸롱 지숙성형전 여자힙합노래 라임쩌는 http://sportstoto-g.com 망상동홀덤바 방동유흥주점 덕지동안마 정가은무한걸스 삼천동홀덤룰 섹스코리아 백점만점아이유 중학생피팅모델 연남동성인게임장 토정동오마하홀덤 상계1동텍사스홀덤 런닝맨유이 한국사이버결재주식 삼가동북창pr http://namedtoto.com 주식수수료계산법 향교동성인게임장 여중생목욕탕 직장인월급 고화질성인동영상다운 정석투자 수입베이비수영복 나소향 효창동리얼돌성인인형 강동동방석집 동교동유흥거리 고림동출장마사지 성인주민번호 증산동홀덤카페 토토랑프로토랑 신대방동홀덤카페 군남면안마 써니데이즈수정노출 정수정미니홈피 자원동홀덤카페 야한상상 소학동대딸방 KOSEF통안채주식 소호동유흥문화 문희준alone 채운동출장마사지 라니아전신시스루 별양동오마하홀덤 블루투스관련주 성체위 신새롬 동회동텍사스홀덤 종로1가홀덤족보 명륜4가포커고수 수청동홀덤족보 고덕동떡집 평화동홀덤카페 청담동토킹bar 용호동토킹bar 투자가 갈소원정답입니다 중곡1동홀덤룰 하모동성인게임장 함라면오마하홀덤 여자나체 부평구인싸포커 방축동북창pr 겨울수혜주 이진우교수 백성향트위터 미국의유명한가수 신호동풀싸롱 녹번동대딸방 싸이신곡 바일레BK 상평동홀덤카페 은행선화동출장마사지 옷벗으면 만지는키스 짬보 금암동텍사스홀덤 2013년신인가수 강화홀덤대회 시스타속바지 벙개벙개 무한공유맥스 섹시가슴골 성덕면텍사스홀덤 게이들이뽑은 남녀고교생장난동영상 효자손제작 가생이닷컴 평화동인싸포커 과천동성인게임장 사사키레미 배부신경차단 어달동홀덤족보 아시클로버연고 외국인매수종목 영웅호걸지연노출 월계동건마 위즈정보기술주식 장기동홀덤대회 AE라리사 제시카직캠 에프엑스와놀다 자수놓기 신영동홀덤카페 박봄허벅지운동 코섹스 봉양동대딸방 서신동성인오락실 부론면홀덤카페 연지동성인게임장 펀드초보 이지애임신 수신면출장마사지 이홍기용준형 2011한국영화 홈캐스트주식 최고의노출녀 야시시나라 미유동산 원당동성인인형체험 즐밤 플짤뜻 복죽동홀덤펍 창조적자본주의 황금성릴게임 용강동키스방 패떳이효리 sexyvideo 지드래곤용준형 박해미몸매 나나우미나나 김선신 운봉읍홀덤카페 정소영 근화동성인오락실 인터넷다빈치 삼성동카지노펍 고메즈 아야세하루카 인창동아로마마사지 백구면홀덤대회 연지동성인게임장 상산곡동오마하홀덤 상왕동안마 공항동립카페 정릉동홀덤카페 사진사이즈 멱곡동룸싸롱 무한걸스2 김옥빈할매 성인용품사이트 용복동성인게임장 플레이엔젤스 삼선동레깅스룸 가평읍오피 이승기이상형 안암동4가인싸포커 게티이미지 제주도대딸방 유이섹시춤 덕암동립카페 스탁마스터 단기매매전략 월계동홀덤카페 초량동풀싸롱 야동만화 대정동방석집 섹시녀 진지희빵꾸똥꾸 섹스하는장면 학성동텍사스홀덤 경정예상 상지석동립카페 영등동오마하홀덤 박민영란제리화보 시와찬미 하이트홀딩스주식 지연가랑이 영천동성인게임장 성덕동홀덤대회 꽁머니사이트 빌리브랜트 설악동오마하홀덤 무료성인애니다운 무악동모바일홀덤 대야미동아로마마사지 양평대딸방 윤예진 누하동유흥거리 모델김소원 레인보우지숙담배 발렌시아가벨로 소향스타킹 둔촌동모바일홀덤 동덕여대수강정정 마초비디오 watch 도렴동성인게임장 비아그라약국판매가격 수민동가라오케 엠카포미닛컴백 당리동풀싸롱 등촌3동텍사스홀덤 긴머리굵은웨이브 색스일본 개봉2동홀덤바 섹시한연예인 클럽프렌즈 전우치마지막회 야심만만2주아민 위크툰 돈의화신시청률 최고다이순신강소라 두정동유흥거리 관심있는남자에게하는행동 폴스미스남성지갑 무한도전영어마을특집 홍은1동홀덤대회 뉴스방송사고동영상 조루증치료비용 효자동인싸포커 하산곡동홀덤카페 원정동아로마마사지 해신동텍사스홀덤 성민희철 http://s-powerball.com 토사랑 중2신사고 이나영과거귀신분장 세바퀴현아노래 내동텍사스홀덤 무료성인자료 장우영주민번호 평화동성인오락실 신사동포커고수 신기동토킹bar 자양4동텍사스홀덤 중동포커고수 상평동카지노펍 노출연예인동영상 토무비 이다해화보 토평동출장마사지 오산동성인오락실 범방동북창pr 성인오락실 조운동텍사스홀덤 도장동텍사스홀덤 옥천면대딸방 버벌진트 마두동성인게임장 와이즈토토승무패 험멜짝퉁 고천동안마 종로구아로마마사지 현자타임스 구의3동성인오락실 ocn편성표 김민아키 나나댄스 배양동유흥주점 번동립카페 포샵으로얼짱만들어주세요 석남동키스방 블랙프릴비키니 2009외국영화 성교육만화보기 신탄진동출장마사지 망월동모바일홀덤 대야면홀덤카페 야잘알닷컴 송윤아설경구루머 mama동방신기 야한색스최강야한동영상1 연수구포커고수 군남면성인인형체험 악보코드 신관동인싸포커 지나같은생각 와스탁 불가리시계줄 추천나이트 봉림동오피 청평면레깅스룸 남규리술집 http://u-sportstoto.com 소도동인싸포커 호흡곤란 지붕뚫고하이킥이기광 엠폴리FC 갈천동오마하홀덤 장화동성인게임장 주산면출장마사지 소녀시대움짤 화양동립카페 해운대노래방 홍제1동홀덤룰 지노트로핀 KPX케미칼주식 수유1동성인게임장 sbs스포츠 미우미우스니커즈 구평동방석집 소양동홀덤룰 수유동나이트 노라조닷컴 마이패프닝 이부진고소영 현빈엘리베이터 광주결혼정보업체 비키니수영복추천 포남동홀덤룰 소리넷 처음처럼현아움짤 니혼햄[1이닝득점] AV쇼미 북한정전협정 그리스수페르리가엘라다 백점만점인피니트 권곡동방석집 디지몬어드벤쳐02 선동오피 용산동리얼돌성인인형 성북동1가홀덤룰 일드2008 성내동안마 수익률게임 아이폰명품악세사리 트리암 홍익동유흥거리 http://powerball-w.com 만화짤방 휘석 수지담배 권수진 바카라노하우 비금도 중구유흥주점 정일훈귀요미플레이어 여성섹스방 영어노래 종로2가홀덤바 어덜트무비 반곡동홀덤카페 정총무 먹튀수사대 간기남청미 수내출장마사지│서현출장마사지│이매출장마사지 비래동유흥문화 코성형수술 유인나볼륨을높여요 이천방석집 아테나e컵 동선동건마 배팅연습 개봉동유흥문화 화성인바이러스박봄 후끈동영상 신종플루수혜주 ev-f500 안전놀이터모음 투자분석 grimm 해외선물프로그램 홍어산란기 오오츠키히비키 업소홍보 삼선동아로마마사지 신관동룸싸롱 노리치시티FC 고림동유흥거리 여친설사 충무동나이트 먹튀업체 이채영쇼핑몰 먹튀폴리스 SportivoBelgrano 참을수없는 웃긴동영상몰래카메라 동현동아로마마사지 avplayer사용법 무한도전웃긴짤 벌바 오리지날바다이야기 배우가하는일 쿨맥스레깅스 천안룸살롱 FNATKFHD 야부리주소 뽑기 먹튀검증스포위키 용산동건마 교동룸싸롱 한류일본방송 신대동리얼돌성인인형 하라미키에화보 금곡동유흥주점 프린트공유 여자걸그룹 2011유망펀드 여자연예인노출사진 섹시원피스쇼핑몰 키움자산운용 섹스동영상감상 역대한국영화흥행순위 먹튀검증사이트먹튀닷컴 오션포카 동교동아로마마사지 만화책다운 봄이미지 일본섹시여자 파워블로그만드는방법 유노윤호복근 씨스타러빙유노출 영통레깅스룸 ccm가수추천 x파일5 2010한국바둑리그 토정동떡집 유승호군대 먹튀폴리스검증업체 글래머크리스탈 AVMANY야동 미우미우지갑가격 헬로비너스새멤버 섹스한국 자녀사랑CMA 지유님 p군 야플TV일본야동 카이스트자살 이승연과100인의여자다이어트 페레가모남자가방 수원립카페 먹튀검증스포위키 사설토토 룸싸롱접대 토토매치 아프리카방송노출 토토로사 수지노출합성 청소면룸싸롱 유니클로팬티 주간증시전망 케이알제2호주식 여자기구 뉴섹스코리아 경원여객 로또당첨번호지역 무한도전러시안룰렛정준하 먹튀보상 타투이스트 국내적립식펀드추천 석대동아로마마사지 엄빠주의소설알집 후기키스방 씨네플러스 노량진동성인용품 메이플스토리초보자육성법 경범죄 우니베르시타테아클루지 집에서할수있는사업 에로틱 대성에너지주식 지나oops뮤비 안전한놀이터찾는법 권유리트렌스젠더 토토커뮤니티 빅사이즈여성속옷 야한망가 부창동성인인형체험 다음주식 의정부단란주점 g컵출렁 눈요기3 gs칼텍스trading직무 써니합사 착한글래머최은정화보 삼동키스방 먹튀업체 다음드슈어맨 상봉동룸싸롱 먹튀신고 핵찌월드 먹튀검증업체순위 거버배변훈련팬티 이슬이비키니 동영상변환프로그램 dj샤인 세동나이트 성인섹스비디오 삼락동리얼돌성인인형 일반인몸매 황정음김용준폭행 약대동나이트 먹튀닷컴 반석동유흥주점 상따차트 로또540 일산서구리얼돌성인인형 유흥업소정보 브렌트코리건토렌트 조권가인 성인동영상다운받는곳 xxx 주식자금 연천읍가라오케 위건순위 공항바카라체험 인기연예인 먹튀폴리스 무공이네 시알리스50mg 박상민눈물잔 중고명품벨트 SM용품 토토다이소 g컵화성인김은영쇼핑몰 40대남자 은계동방석집 남자발 여자성형 효린오늘같은밤이면 해변직촬 남자아이돌화보 토렌트올 외국인기관 섹스망가 와이즈캠프가격 쌍용양회주식 어벤져스배트맨 파워그라 임정은 홍콩인사이드 돈버는앱 미국섹스비디오 영통방석집 토토브라우져검색어 영화배우김현아 논현동방석집 로또당첨비법 아이유허벅지직캠 김민지아나운서 에일리비키니 대평동립카페 섹스신 정가은나는펫 교문동떡집 영성동가라오케 pigav 판타지야오이만화책 도드리 베트남복권 해피아이돌핵 솔브커플속옷 http://byulgame.com 일억굴리기 선동립카페 피망로우바둑이 미국성인방송 40대투잡 구리키스방 강북나이트 알바카노 부부성교육 보디가드속옷 디오텍주식 은행동노래방 씨스타보라과거 만년동노래방 현대엔지니어링주가 전우치1회다시보기 클럽댄스배우기 무료성인영화보는곳 강남노래주점 트위터소라넷 영화나는펫 브라이틀링크로노맷 모두프리 FC뉘른베르크(Am) 인터넷성인영화 꿀벅지걸 목달동키스방 나가수 게임코스프레 freeporn 재무관리교육 유니슨주식 프라다링크 레이싱게임 블로그지수확인 호두코믹스새주소 손빨넷 걸스데이소진과거 수술용메스 보솜이기저귀 주식조회 서동퍼블릭룸 산북동레깅스룸 어남동레깅스룸
전화번호 : 영업시간 :
홈페이지 : 위치정보 :

댓글목록

등록된 댓글이 없습니다.